| HOME >> MEDICINE >> TECHNOLOGY |
The results showed that intravenous (IV) and subcutaneous (SC) MIRCERA maintained stable Hb levels in dialysis patients over and under 65 years of age who were successfully switched from the frequently administered agents, epoetin alfa and beta. The study investigators also noted:
-- Minimal changes from baseline to evaluation in mean Hb levels in patients less than or equal to 65 and >65 years (-0.18 vs -0.34 g/dL), meaning that the elderly can be treated with confidence.
-- Minimal mean Hb changes from baseline to evaluation in male and female patients treated with MIRCERA (-0.21 vs -0.30 g/dL).
MIRCERA treatment was well tolerated, with a safety profile characteristic of the patient population.
"With more elderly people needing dialysis treatment, doctors will need effective medications that can improve the way we manage renal anaemia. These findings underscore the value of MIRCERA in meeting a goal of anaemia management, namely haemoglobin stability," said Dr. Elias David Neto, Centro de Nefrologia e Transplante Renal, University of Sao Paulo, Sao Paulo, Brazil.
Bearing the Burden of Chronic Kidney Disease: The Prevalence of Dialysis in an Aging Population
Dialysis is the only treatment option for end stage renal
disease patients who are either waiting for or not a candidate for
a renal transplant. The number of people over the age of 65 with
end stage renal disease is on the rise because of an aging
population and the diabetes epidemic.(ii),(iii) In fact, more than
50 percent of the people on dialysis are over 60 years of age.(iv)
Further, it is known t
'"/>